文献速递临床试验与 GCP基础与转化研究

阿尔茨海默病通路睡眠研究(ALPS):通过慢波睡眠改善认知与阿尔茨海默病病理的实验性随机对照试验

The Alzheimer's Pathways Sleep Study (ALPS): an experimental randomized controlled trial to improve cognition and Alzheimer's pathophysiology through slow-wave sleep.
PubMed 文献 · Trials · 2026-02-19

ALPS是一项随机对照试验,计划纳入116名65-85岁睡眠差的老年人,随机分为卧床时间限制组(卧床时间为习惯卧床时间的85%,持续4周)与注意力匹配对照组(维持习惯卧床时间4周)。主要结局为慢振荡绝对功率、记忆编码时海马激活、血浆Aβ1-42及过夜词语配对记忆保持。

要点

  • 卧床时间限制至习惯卧床时间85%持续4周,旨在通过稳态睡眠驱动力增加慢波活动。
  • 主要结局包括慢振荡绝对功率、海马激活、血浆Aβ1-42和过夜词语配对记忆保持。
  • 需实施所描述的安全措施以最小化卧床时间限制相关风险。

核心结论

  • 通过卧床时间限制行为性增强稳态睡眠驱动力是改善记忆表现和阿尔茨海默病病理的有前景方法。
  • 应实施所描述的安全措施以最小化卧床时间限制相关风险。

研究设计与样本

  • ALPS是一项随机对照试验,旨在行为性增加睡眠差的老年人的慢波活动。
  • 目标入组116名65-85岁参与者,随机分配至卧床时间限制干预或注意力匹配对照干预。

主要发现

  • 卧床时间限制组遵循将卧床时间限制至习惯卧床时间85%的睡眠计划,持续4周;对照组维持习惯卧床时间4周。
  • 两组在4周内均通过日记、体动记录仪、报到电话和困倦评分进行监测。
  • 四个具体目的的主要结局为:非快速眼动睡眠中慢振荡(0.5-1 Hz)范围的绝对功率、记忆编码时海马激活、血浆Aβ1-42、过夜词语配对记忆保持。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Slow-wave activity (0.5-4 Hz electroencephalographic activity) during non-rapid eye movement sleep is consistently associated with better cognitive performance in older adults. Slow-wave activity is known to regulate synaptic plasticity and may thereby mitigate excitotoxicity and accumulation of Alzheimer's pathology. Paradoxically, longer total sleep times in older adults are often associated with poorer cognition and general health. Conventional behavioral sleep treatments robustly increase sleep efficiency and sleep time, but do not consistently enhance slow-wave activity and have shown only subtle effects on cognition. Thus, enhancement of slow-wave activity may be a critical target for sleep-based cognitive enhancement. The Alzheimer's Pathways Sleep Study (ALPS) uses a novel time-in-bed (TiB) restriction intervention designed to increase slow-wave activity through homeostatic sleep drive and assesses improvements in measures of excitotoxic hippocampal hyperactivation, plasma levels of amyloid beta (Aβ), and overnight memory retention. METHODS: ALPS is a randomized controlled trial designed to increase slow-wave activity behaviorally in older adults with poor sleep. Target enrollment is 116 participants aged 65-85. Participants are randomized to a TiB restriction intervention or an attention-matched control intervention. Participants randomized to TiB restriction follow a sleep schedule restricting their TiB to 85% of their habitual TiB for 4 weeks. The control group follows their habitual TiB for 4 weeks. Both groups are monitored with diary, actigraphy, check-in calls, and sleepiness ratings over the 4 weeks. The primary outcomes for four specific aims are (1) absolute power in the slow oscillation (0.5-1 Hz) range during non-rapid eye movement sleep, (2) hippocampal activation during memory encoding, (3) plasma Aβ1-42, and (4) overnight word pair memory retention. Here we describe how the ALPS intervention is administered, the protocols and scripts implemented to maximize adherence and safety, and outcomes measured to test the proposed conceptual model linking slow-wave activity with excitotoxic hyperactivation, Alzheimer's pathophysiology, and memory performance. DISCUSSION: Behavioral enhancement of homeostatic sleep drive through TiB restriction is a promising approach to improve memory performance and Alzheimer's pathophysiology. Safety measures, as described here, should be implemented to minimize risks associated with TiB restriction. TRIAL REGISTRATION: ClinicalTrials.gov NCT05138848. Registered on December 1, 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Dong YC, Habte RF, Dessa KM, et al. The Alzheimer's Pathways Sleep Study (ALPS): an experimental randomized controlled trial to improve cognition and Alzheimer's pathophysiology through slow-wave sleep. Trials. 2026. PMID: 41715219. doi:10.1186/s13063-026-09505-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。